.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05B_AntiParathyroidAgents.H05BX06_Evocalcet.Evocalcet .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05B_AntiParathyroidAgents.H05BX06_Evocalcet.Evocalcet| name: | Evocalcet |
| ATC code: | H05BX06 | route: | oral |
| n-compartments | 2 |
Evocalcet is a calcimimetic agent used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. It acts by increasing the sensitivity of the calcium-sensing receptors on parathyroid cells, thereby reducing parathyroid hormone (PTH) secretion. Evocalcet was approved in Japan and is used as an alternative to cinacalcet with favorable gastrointestinal tolerability.
Pharmacokinetic parameters reported for healthy adult subjects (Japanese), single oral administration.